Dr. Omkar S Marathe
Claim this profileThe Oncology Institute of Hope and Innovation
Studies Colorectal Cancer
Studies Non-Small Cell Lung Cancer
18 reported clinical trials
31 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
NRAS negative
2Non-Small Cell Lung Cancer
Stage IV
MET positive
MET negative
Affiliated Hospitals
Clinical Trials Omkar S Marathe is currently running
ONC-392 vs Chemotherapy
for Lung Cancer
This trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Recruiting2 awards Phase 310 criteria
Chemo-Immunotherapy
for Breast Cancer
The goal of this clinical trial is to compare the safety and efficacy of eftilagimod alpha (efti) in combination with paclitaxel standard of care chemotherapy in participants with metastatic breast cancer. The main questions it aims to answer are: * What is the optimal biological dose (OBD) of efti in combination with weekly paclitaxel chemotherapy? * Can efti combined with weekly paclitaxel chemotherapy prolong overall survival in participants with metastatic breast cancer if compared to weekly paclitaxel chemotherapy alone? In the first component of the trial (phase 2, lead-in) researchers will compare two groups (different dose levels of efti in combination with standard chemotherapy) to see if the treatment is safe and well tolerated and evaluate which is the optimal biological dose. In the second component of the trial (phase 3) researchers will assess if the treatment of metastatic breast cancer with the optimal biological dose of efti in combination with paclitaxel is superior compared to chemotherapy alone (placebo-controlled). The treatment concept of each trial component consists of a chemo-immunotherapy phase followed by an immunotherapy phase. In the first phase participants will be treated with efti plus paclitaxel chemotherapy or placebo plus paclitaxel chemotherapy. After completion of the chemotherapy per standard of care, participants will be treated with the study agent alone.
Recruiting0 awards Phase 2 & 35 criteria
More about Omkar S Marathe
Clinical Trial Related3 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Omkar S Marathe has experience with
- Trilaciclib
- Docetaxel
- Placebo
- MEN1611
- Cetuximab
- OQL011
Breakdown of trials Omkar S Marathe has run
Colorectal Cancer
Non-Small Cell Lung Cancer
Tumors
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Omkar S Marathe specialize in?
Omkar S Marathe focuses on Colorectal Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Omkar S Marathe currently recruiting for clinical trials?
Yes, Omkar S Marathe is currently recruiting for 5 clinical trials in Anaheim California. If you're interested in participating, you should apply.
Are there any treatments that Omkar S Marathe has studied deeply?
Yes, Omkar S Marathe has studied treatments such as Trilaciclib, Docetaxel, Placebo.
What is the best way to schedule an appointment with Omkar S Marathe?
Apply for one of the trials that Omkar S Marathe is conducting.
What is the office address of Omkar S Marathe?
The office of Omkar S Marathe is located at: The Oncology Institute of Hope and Innovation, Anaheim, California 92801 United States. This is the address for their practice at the The Oncology Institute of Hope and Innovation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.